Evidence map›Paper›PMID 30872765›Full record

ArticleScientific reports2019

Network Pharmacology-Based identification of pharmacological mechanism of SQFZ injection in combination with Docetaxel on lung cancer.

Tan Li, Zhu Baochen, Zhang Yue, Wang Cheng, Wu Yali, Sun Zongxi, Zhang Wantong, Lu Yang, Du Shouying

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Tan LiBeijing University of Chinese Medicine, Beijing, 100029, China.
Zhu BaochenBeijing University of Chinese Medicine, Beijing, 100029, China.
Zhang YueLivzon Pharmaceutical Group Inc., Zhuhai, 519020, China.
Wang ChengBeijing University of Chinese Medicine, Beijing, 100029, China.
Wu YaliBeijing University of Chinese Medicine, Beijing, 100029, China.
Sun ZongxiBeijing University of Chinese Medicine, Beijing, 100029, China.
Zhang WantongChina Academy of Chinese Medicine Sciences, Xiyuan hospital, Beijing, 100091, China.
Lu YangBeijing University of Chinese Medicine, Beijing, 100029, China. landocean28@163.com.
Du ShouyingBeijing University of Chinese Medicine, Beijing, 100029, China. dushouying@263.com.
Beijing University of Chinese Medicine · CNChina National Pharmaceutical Group Corporation (China) · CNXiyuan Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Docetaxel is the widely-used first-line therapy to treat lung cancer around the world. However, tumor progression and severe side effect occurred in some patients with docetaxel treatment. Most of the side effects were caused by immunocompromise, which limits the long-term use of docetaxel. Shenqi Fuzheng (SQFZ) injection has been used as adjuvant therapy to treat lung cancer which may enhance immunity as well. Owing to the complexity of drug combination, the mechanism of SQFZ injection in combination with docetaxel on lung cancer remains unclear. Therefore, a network pharmacology-based strategy was proposed in this study to help solve this problem. Network pharmacology approach comprising multiple components, candidate targets of component and therapeutic targets, has been used in this study. Also, in vivo and in vitro experiment was applied to verify the predicted targets from network pharmacology We established mouse lung cancer model and inject with docetaxel and SQFZ injection. Tumour weight, spleen index, thymus index, immunohistochemical staining and ELISA were conducted to evaluate the effect and underlying mechanisms of docetaxel and SQFZ injection. Besides A549 cells were also administrated by docetaxel and SQFZ.The indexes BCL2, CASP3 and CASP9 were determined after administration. The results indicated that combination of SQFZ and docetaxel could reduce tumour weight, enhance the spleen index, thymus index. Meanwhile, it could improve the activity of caspase-3 and IL-2 in mice and caspase-3, caspase-9 in A549 cell and inhibit the activity of BCL-2 in A549 cell, which verified the potential protective targets predicted by network pharmacology. In conclusion, combination of SQFZ and docetaxel could increase the curative effect by inducing tumour to apoptosis and play a key role on immunoprotection to reduce side effects.

Indexed as

A549 CellsAnimalsAntineoplastic AgentsApoptosisCaspase 3Chromatography, High Pressure LiquidDocetaxelDrugs, Chinese HerbalDrug Therapy, CombinationHumansInterleukin-2Lung NeoplasmsMaleMass SpectrometryMetabolic Networks and PathwaysMiceAntineoplastic AgentsCaspase 3DocetaxelDrugs, Chinese HerbalInterleukin-2Proto-Oncogene Proteins c-bcl-2shenqi fuzheng

Identifiers

PMID30872765
PMCPMC6418214
OpenAlexW2921307754

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.